Official Publications Summit Therapeutics Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 23/01/2026 GMT			5-day change	1st Jan Change
16.49 ^USD	-5.07%		-3.23%	-5.72%

01-13	AbbVie Enters Cancer Treatment Space via RemeGen Licensing Deal, UBS Says	MT
01-12	Summit Therapeutics Inc. Announces Submission of Biologics License Application to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC	CI

No official publication found